Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the "Company" or "Fulgent") about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, among others, those related to long-term upside or value, management of risk, anticipated growth and positioning, ad ...

BREAKING: Futures Mixed On Trump Comments; Fed, Huge Earnings Due Genetic testing leader GeneDx Holdings (WGS) is Monday's pick for IBD 50 Growth Stocks To Watch. The medical services stock is climbing in a seven-week-long consolidation pattern as the company's earnings report approaches. GeneDx turned profitable in 2024, and analysts expect meteoric earnings growth for its third quarter. The IBD 50 genetics testing stock was recently highlighted as an IBD Breakout… Take a Trial Today Get instant access to ...

Core Insights - Fulgent Genetics experienced a significant stock price increase of over 8% following its second-quarter earnings release, contrasting with a nearly 2% decline in the S&P 500 index [1] Financial Performance - The company reported second-quarter revenue of nearly $82 million, representing a year-over-year increase of more than 15% [2] - Non-GAAP adjusted net income fell sharply by 56% to just over $2 million, equating to $0.07 per share [2] Analyst Expectations - Analysts had anticipated worse results, projecting an adjusted bottom-line loss of $0.18 per share on revenue of only $76 million [4] Strategic Progress - Fulgent attributed its better-than-expected results to diversification efforts, with CEO Ming Hsieh noting progress in growing revenue from laboratory services and advancing clinical trials for therapeutic development [4] Future Guidance - The company raised its revenue and adjusted bottom-line guidance for full-year 2025, now expecting "core" revenue of approximately $320 million and an adjusted net loss of $0.35 per share, surpassing analyst projections of a $0.55 net loss and revenue under $311 million [5]

Industry Overview - The Medical Services sector is undergoing significant transformation driven by technological advancements, value-based care adoption, and a focus on patient-centric solutions and precision medicine [1] - The industry includes various service providers such as pharmacy benefit managers, contract research organizations, and healthcare workforce solution providers, moving from volume-based to value-based care [3] Market Trends - The global healthcare analytics market was valued at $53.1 billion in 2024, with a projected CAGR of 21.4% from 2025 to 2034, benefiting various stakeholders [2] - The digital health market is expected to grow at a CAGR of 9.2% from 2024 to 2028, while the big data in healthcare market is estimated to increase from $78 billion in 2024 to $540 billion by 2035, representing a CAGR of 19.20% [4] - The demand for skilled nursing professionals is surging, with a projected shortfall of over 100,000 healthcare workers by 2028, including 73,000 nursing assistants [2] Staffing Challenges - The healthcare staffing shortage is exacerbated by the aging population and the exit of frontline workers due to the COVID-19 pandemic, with WHO projecting a shortfall of 9.9 million healthcare professionals by 2030 [5] - Hospitals have seen a 15.6% increase in labor expenses per adjusted discharge compared to pre-pandemic levels due to rising labor costs [5] Nursing Care Market - The role of nurses is evolving with advancements in medical technologies, and the employment of nurse anesthetists, nurse midwives, and nurse practitioners is projected to grow 40% from 2023 to 2033 [6] Industry Performance - The Medical Services Industry has underperformed compared to its sector and the S&P 500, with a collective loss of 13.4% over the past year [10] - The industry is currently trading at a forward P/E of 14.6X, lower than the S&P 500's 21.9X and the sector's 19.3X [13] Investment Opportunities - GeneDx, CVS Health, and BrightSpring are identified as stocks with strong earnings outlooks, with GeneDx expected to have a 336% earnings growth rate in 2025 [19][20][22][26] - CVS Health is focusing on advanced technological capabilities and has projected earnings growth rates of 12.6% and 14.3% for 2025 and 2026, respectively [22][23] - BrightSpring is improving care quality and is expected to see an 82.1% earnings growth rate in 2025 [26][27]

Core Points - 23andMe is seeking a new owner as part of its Chapter 11 bankruptcy protection proceedings to maximize business value and address operational and financial challenges [1][4] - The company emphasizes the importance of customer data protection in any potential sale, stating that it remains committed to user privacy [2][10] - Following court approval, 23andMe will work with an independent investment banker to solicit offers from interested buyers over a 45-day period, with an auction planned if multiple offers are received [4][7] Financial and Legal Context - The company filed for Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Missouri, indicating significant operational and financial difficulties [1] - Litigation related to a 2023 data breach, which exposed the genetic data of nearly 7 million customers, has increased liabilities and contributed to the bankruptcy filing [5][6] - 23andMe agreed to pay $30 million and provide three years of security monitoring to settle a lawsuit regarding the data breach [6] Management and Strategic Moves - CEO Anne Wojcicki has resigned to position herself as an independent bidder for the company [7][8] - The company has reached out to numerous potential buyers, indicating a proactive approach to finding a new owner [7]

Market Overview - U.S. stock markets have experienced significant volatility, with major indexes like the Dow, S&P 500, and Nasdaq Composite in negative territory year to date, and the S&P 500 and Nasdaq in correction zones [1] - The mid-cap S&P 400 is also in the red, while the small-cap Russell 2000 is in bear territory year to date [1][2] Economic Concerns - Market participants are worried about the Trump administration's tariff and trade policies and their potential impact on U.S. economic growth and inflation [2] - Recent economic data indicates a weakening U.S. economy, with retail sales, industrial production, manufacturing PMI, housing sector data, and consumer confidence all falling below expectations [2] Stock Performance - A select group of stocks has shown price strength despite the overall market downturn, with five notable stocks identified: DRDGOLD Ltd. (DRD), GeneDx Holdings Corp. (WGS), EverQuote Inc. (EVER), HCI Group Inc. (HCI), and Alibaba Group Holding Ltd. (BABA) [3] Stock Screening Criteria - Stocks must show a percentage change in price greater than zero over the last four weeks and greater than 10% over the last 12 weeks to indicate sustained momentum [5] - A Zacks Rank of 1 (Strong Buy) and an average broker rating of 1 or 2 are also important indicators of potential performance [6] - Stocks should be trading at a minimum price of $5 and have a current price/52-week high-low range greater than 85% to ensure they are near their highs [7] Individual Stock Highlights - **DRDGOLD Ltd. (DRD)**: Stock price increased by 34.6% in the past four weeks, with an expected earnings growth rate of 29.3% for the current year [8] - **GeneDx Holdings Corp. (WGS)**: Stock price rose by 29% in the past four weeks, with expected earnings growth exceeding 100% for the current year [10] - **EverQuote Inc. (EVER)**: Stock price surged by 22.7% in the past four weeks, with expected earnings growth of 34.1% for the current year [12] - **HCI Group Inc. (HCI)**: Stock price increased by 16.9% in the past four weeks, with expected earnings growth exceeding 100% for the current year [14] - **Alibaba Group Holding Ltd. (BABA)**: Stock price advanced by 13.1% in the past four weeks, with expected earnings growth of 23.1% for the next year [17]